NCT01054937

Single Dose Study With 4SC-203 in Healthy Volunteers

First-in-Man, Randomised, Double-Blind, Placebo-Controlled, Single Dose Escalation Study of the Novel Compound 4SC-203 in Young Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: 4SC AG · Industry
• Sex: Male
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The purpose of the study is to evaluate safety and tolerability of 4SC-203 after a single dose administration in healthy volunteers.

Conditions

• Acute Myeloid Leukemia

Interventions

Type	Name	Description
DRUG	4SC-203	i.v. administration
DRUG	Placebo	i.v. administration

Timeline

• Start date: 2010-01-01
• Primary completion: 2010-11-01
• Completion: 2010-11-01
• First posted: 2010-01-22
• Last updated: 2011-01-13

Locations

1 site across 1 country: Germany